• Triptolide (PG490): Mechanisms and Research Use

  2026-08-20

  Triptolide, also known as PG490, is a nanomolar-potency natural product used in cancer research, immunology, and inflammation studies. Its reported actions include IL-2 suppression, NF-κB transcriptional inhibition, CDK7-associated RNA polymerase II loss, matrix metalloproteinase reduction, and apoptosis induction.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-08-20

  This case report and literature review describes the first reported clinical use of anlotinib for metastatic intra-abdominal desmoplastic small round cell tumor, with marked reduction of metastatic lymph nodes after four treatment cycles and tolerable fatigue and hypertriglyceridemia. The report is hypothesis-generating rather than confirmatory, but it shows how a multi-target tyrosine kinase inhibitor may provide a treatment option when standard multimodal therapy fails.

• Oligomycin A for Mitochondrial Bioenergetics

  2026-08-19

  Oligomycin A provides a controlled way to separate ATP-linked respiration from broader metabolic stress in cell and cancer models. This practical guide connects mitochondrial flux assays with ROS, viability, and macrophage immunometabolism workflows while emphasizing solvent control and interpretation limits.

• Berbamine hydrochloride: HCC Assay Workflows

  2026-08-19

  Build reproducible cancer research workflows around Berbamine hydrochloride by combining pathway readouts, dose-response profiling, and ferroptosis-focused validation. The approach distinguishes direct viability effects from changes in NF-κB, STAT3, calcium, iron, and lipid-peroxidation biology.

• HDAC8, AKT, and Resistance to MEK Inhibition

  2026-08-18

  The reference study identifies an HDAC8–PLCB1/DESC1 regulatory axis that activates AKT when MEK1/2–ERK signaling is inhibited in colorectal cancer and melanoma models. Its combination of transcriptomic discovery and causal perturbation suggests that resistance may be addressed by targeting compensatory signaling rather than intensifying MEK inhibition alone.

• CDC42, NTCP Trafficking, and HBV Entry

  2026-08-18

  The reference study identifies CDC42 as a regulator of hepatitis B virus entry through two separable mechanisms: Rab11-dependent delivery of NTCP to the plasma membrane and CDC42-dependent macropinocytosis. These findings expand the conventional model of HBV uptake beyond clathrin-mediated endocytosis and highlight receptor trafficking as a determinant of hepatocyte susceptibility.

• γH2AX DNA Damage Detection Kit for DSB Research

  2026-08-17

  Translate radiation, drug, and genotoxic stress into a measurable nuclear signal with the γH2AX DNA Damage Detection Kit. Its red Cy5 γ-H2AX foci and blue DAPI counterstain support microscopy, repair-kinetics studies, and high-content comparisons such as FLASH-RT radiosensitization.

• Firefly Luciferase mRNA Workflow

  2026-08-17

  Build more interpretable mRNA delivery screens with a Cap1-capped, 5-moUTP modified reporter that separates transcript performance from carrier effects. The workflow combines controlled handling, functional luminescence readouts, and low-cost mixer comparisons for cell-based assays and carefully qualified imaging studies.

• Pioglitazone (B2117) for Reliable Cell Assays

  2026-08-16

  Learn how Pioglitazone (SKU B2117) can improve interpretation of viability, proliferation, and inflammatory-cell assays through controlled PPARγ activation, solvent handling, and orthogonal validation. This scenario-based guide connects receptor pharmacology with practical workflows in metabolic and inflammation research.

• AI-10-49 and the Logic of Fusion-Driven AML

  2026-08-15

  AI-10-49 offers translational researchers a mechanism-first way to interrogate inv(16) acute myeloid leukemia: disrupt the CBFβ-SMMHC–RUNX1 interaction, measure restoration of RUNX1 activity, and connect target engagement to the N-MYC/eIF4G1 survival axis.

• Podophyllotoxin: Assay Design for MDR Cancer Models

  2026-08-14

  Podophyllotoxin is a powerful probe for linking microtubule disruption to cell-cycle arrest, apoptosis, and drug resistance. This guide focuses on mechanistic assay design, native-compound controls, and how derivative research can inform—but not replace—experiments with research-grade Podophyllotoxin.

• Flavopiridol and ER Stress: Assay Design

  2026-08-14

  Flavopiridol and L868275 provide a mechanistically distinct way to examine CDK-dependent proliferation alongside endoplasmic reticulum stress. This guide translates intestinal stem-cell findings into rigorous assay decisions for cancer research without conflating cell-cycle arrest with ER-stress injury.

• FLAG tag Peptide (DYKDDDDK): Facts & Workflow

  2026-08-13

  The FLAG tag Peptide (DYKDDDDK) is an 8-amino-acid synthetic epitope tag for recombinant protein detection and purification. Its defined sequence supports competitive elution from anti-FLAG M1 and M2 affinity resins, but the product is not intended to elute 3X FLAG fusion proteins.

• 3-Aminobenzamide PARP-IN-1: Applied Workflows

  2026-08-13

  Build reproducible PARP inhibition workflows for oxidative-stress, vascular, renal, and host-response assays with 3-Aminobenzamide (PARP-IN-1). This guide connects practical dose-finding and assay controls with the coronavirus macrodomain study while clearly separating established evidence from exploratory applications.

• GI 254023X: Selective ADAM10 Inhibitor

  2026-08-12

  GI 254023X is a selective ADAM10 inhibitor with a supplier-reported ADAM10 IC50 of 5.3 nM and more than 100-fold selectivity over ADAM17. Preclinical data connect ADAM10 inhibition with Notch1 signaling modulation, protection against Staphylococcus aureus α-hemolysin, and vascular integrity enhancement in mouse models.

687 records 2/46 page Previous Next 12345 下5页 Last page